Related Experiment Video

Updated: Jul 4, 2026

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?

A Gassas1, S Afzal, M K Ishaqi

  • 1Division of Haematology/Oncology/BMT, Hospital for Sick Children, University of Toronto, Ontario, Canada. adam.gassas@sickkids.ca

Bone Marrow Transplantation
|July 1, 2008
PubMed

Insights

Allogeneic hematopoietic stem cell transplant (HSCT) for children with standard-risk acute myeloid leukemia (AML) in first complete remission (CR1) shows promising results. This study indicates favorable survival and low treatment-related mortality (TRM) in young patients.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) for pediatric standard-risk acute myeloid leukemia (AML) in first complete remission (CR1) remains a topic of debate.
  • Previous studies have reported varying outcomes for this patient population.

Purpose of the Study:

  • To evaluate the efficacy and safety of matched sibling donor HSCT in children with standard-risk AML in CR1.
  • To compare outcomes with existing literature.

Main Methods:

  • Retrospective review of 32 children with standard-risk AML who underwent matched sibling donor HSCT in CR1 between 1995 and 2004.
  • Analysis of event-free survival (EFS), overall survival (OS), and treatment-related mortality (TRM).

Main Results:

  • With a median follow-up of 76 months, the 3-year EFS was 0.74 (95% CI: 0.57-0.88) and OS was 0.81 (95% CI: 0.66-0.93).
  • Only one patient experienced TRM, indicating minimal toxicity.
  • These results compare favorably to larger studies (e.g., MRC-UK 10 and 12) reporting 60-62% EFS.

Conclusions:

  • Matched sibling donor HSCT in CR1 offers encouraging outcomes for children with standard-risk AML.
  • The procedure demonstrates a favorable safety profile with low TRM in this cohort.
  • These findings support the consideration of HSCT in this specific pediatric AML subgroup.

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...